Allergan Settles Botox Off-Label Claims For $600M

Law360, New York (September 1, 2010, 3:01 PM EDT) -- Allergan Inc. reached a $600 million settlement with the U.S. Department of Justice on Wednesday to resolve criminal and civil claims stemming from the company's marketing of off-label uses for its blockbuster wrinkle-treating drug Botox.

Allergan has agreed to plead guilty to a misdemeanor misbranding charge and will cough up $375 million for a criminal fine and forfeiture, as well as $225 million to fund a civil settlement with the federal government and several states. The global settlement must be approved by the U.S. District Court...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.